BCRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BCRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2025-04-06), BioCryst Pharmaceuticals's share price is $6.83. BioCryst Pharmaceuticals's GF Value is $10.44. Therefore, BioCryst Pharmaceuticals's Price-to-GF-Value for today is 0.65. Based on the relationship between the current stock price and the GF Value, GuruFocus believes BioCryst Pharmaceuticals is Possible Value Trap, Think Twice.
The GF Value represents the intrinsic value of a stock, determined using GuruFocus' proprietary methodology. The GF Value Line on our stock Summary page provides an estimate of the stock’s fair-trading value.
To calculate this value, GuruFocus follows these steps:
GuruFocus believes that the GF Value Line represents the fair value at which a stock should trade. Stock prices typically fluctuate around this line. If a stock’s price is significantly above the GF Value Line, it is considered overvalued, and its future returns are likely to be lower. Conversely, if the stock price is significantly below the GF Value Line, its future returns are likely to be higher.
Please note that "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.
BioCryst Pharmaceuticals (NAS:BCRX) GF Value Explanation
Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 ratings:
Posssible Evaluations | All-in-One Screener Examples (2) |
Possible Value Trap, Think Twice (1) | Predictable Companies that possibly be Value Traps |
Significantly Overvalued | Predictable Companies which are Significantly Overvalued |
Modestly Overvalued | Predictable Companies which are Modestly Overvalued |
Fairly Valued | Predictable High Quality Companies which are Fairly Valued |
Modestly Undervalued (3) | Predictable High Quality Companies which are Modestly Undervalued |
Significantly Undervalued (3) | Predictable High Quality Companies which are Significantly Undervalued |
(1) "Possible Value Trap, Think Twice" applies to companies that appear significantly undervalued but are either experiencing a long-term business decline or facing financial distress.
(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.
(3) A sufficient margin of safety exists only when the stock is undervalued.
BioCryst Pharmaceuticals's Price-to-GF-Value for today is calculated as
Price-to-GF-Value | = | Share Price | / | GF Value |
= | 6.83 | / | 10.44 | |
= | 0.65 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Nancy J Hutson | director | 64 MONTAUK AVENUE, STONINGTON CT 06378 |
Amy E Mckee | director | 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703 |
Machelle Sanders | director | C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560 |
Theresa Heggie | director | 4505 EMPEROR BOULEVARD, SUITE 200, DURHAM NC 27703 |
Alan G Levin | director | ACETO CORP., 4 TRI HARBOR CT., PORT WASHINGTON NY 11050 |
Steve Aselage | director | 6300 DUMBARTON CIRCLE, FREMONT CA 94555 |
Vincent Milano | director | C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341 |
Helen M. Thackray | director | C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879 |
Anthony Doyle | officer: Chief Financial Officer | 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703 |
Steven K Galson | director | C/O BIOCRYST PHARMACEUTICALS, INC., 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703 |
Charles K Gayer | officer: Vice President and CCO | 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703 |
Alane P Barnes | officer: VP, General Counsel & Corp Sec | 1929 BRASSFIELD ROAD, RALEIGH NC 27614 |
Jon P Stonehouse | director, officer: CEO | 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244 |
Michael L Jones | officer: Exec Director, Finance - PAO | 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703 |
Yarlagadda S Babu | officer: VP Drug Discovery | 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244 |
From GuruFocus
By Marketwired • 02-24-2025
By GuruFocus News • 02-25-2025
By GuruFocus News • 02-20-2025
By Marketwired • 03-06-2025
By GuruFocus News • 02-12-2025
By GuruFocus News • 03-06-2025
By Marketwired • 01-06-2025
By Marketwired • 02-19-2025
By Marketwired • 02-04-2025
By GuruFocus News • 11-05-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.